Posted by Michael Wonder on 06 Nov 2018
FDA approves novel single-vial formulation of Egrifta
5 November 2018 - Theratechnologies is pleased to announce that the FDA in the United States has approved the new single-vial formulation of Egrifta (tesamorelin for injection).
Egrifta is a growth hormone-releasing factor analog and is the only FDA- approved treatment for excess abdominal visceral adipose tissue in HIV-infected patients with lipodystrophy.
The novel formulation, currently known as “F4”, is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy which is the same indication as the original two-vial formulation of Egrifta approved by the FDA.
